Hepatitis A and B Vaccination Industry Size, Share & Growth Forecast 2033

Hepatitis A and B Vaccination by Application (Government Institution, Private Sector, Other), by Types (Hepatitis A Vaccination, Hepatitis B Vaccination), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Hepatitis A and B Vaccination Market Size | CAGR 7.4 Forecast 2033

Hepatitis A and B Vaccination Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hepatitis A and B Vaccination Market Overview

The Hepatitis A and B Vaccination market encompasses vaccines that prevent hepatitis A, hepatitis B, and combined A‑B infections across public health programs, private clinics, and travel medicine. As global immunization initiatives intensify, the market is pivotal for reducing viral hepatitis‑related morbidity and mortality. The Hepatitis A and B Vaccination market size reached approximately USD 7.0 billion in 2025, and the growth outlook projects a compound annual growth rate (CAGR) of ~7% through the 2026‑2033 market forecast, driven by expanding government vaccination mandates, rising awareness of hepatitis transmission risks, and innovations in combination vaccine formulations. This industry expansion reflects heightened demand in high‑burden regions and increasing adoption of single‑dose and thermostable technologies.

Loading chart…

Three forces are shaping the market: (1) Regulatory momentum, as WHO prequalification and national immunization schedules broaden vaccine eligibility; (2) Technological innovation, highlighted by the rise of combination A‑B vaccines and needle‑free delivery systems that improve compliance; and (3) Supply‑chain resilience, with manufacturers diversifying production across Asia‑Pacific and Europe to meet surging demand. The Asia‑Pacific region remains the largest market, accounting for over 45% of global sales, while Latin America emerges as the fastest‑growing region, propelled by new public‑health funding and expanded outreach to underserved populations. These dynamics underscore a robust trajectory for the Hepatitis A and B Vaccination market through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.21 billion
Growth rate	CAGR of 7.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; Merck; Sanofi; Sinovac; Zhejiang Pukang; Changchun Institute of Biological Products; KM Biologics; IMBCAMS; Convac; NCPC; Bio Kangtai; Dynavax; Hissen; LG Life Sciences; Serum Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Hepatitis A and B Vaccination market is at a pivotal juncture, shaped by evolving public‑health priorities, technological advances, and macro‑economic forces that together define its growth trajectory.

Growth Drivers2 items

Expansion of national immunization programs across emerging economies, propelled by WHO’s updated hepatitis vaccination guidelines and increased public‑health funding, is driving higher vaccine uptake and directly expanding the Hepatitis A and B Vaccination market size.

Rising adult travel and migration to hepatitis‑endemic regions, coupled with employer‑driven health benefits, is prompting private insurers to reimburse combined Hepatitis A/B vaccines, thereby accelerating the market growth forecast and broadening the addressable adult population.

Restraints2 items

Stringent cold‑chain requirements, especially for combination vaccines, inflate distribution expenses and limit price flexibility for low‑margin manufacturers, thereby suppressing overall market size expansion and deterring entry in cost‑sensitive regions.

Patent expiries of leading Hepatitis A/B combination products open the market to biosimilars, yet complex regulatory pathways and uncertain reimbursement frameworks in major economies constrain rapid market penetration and limit short‑term revenue upside.

Opportunities2 items

Investments in single‑dose, thermostable vaccine platforms can eliminate cold‑chain dependencies, unlocking rural and remote distribution channels, expanding the addressable population base, and positively influencing the Hepatitis A and B Vaccination market growth forecast.

Strategic alliances between biotech innovators and global health NGOs facilitate subsidized rollout programs, creating new revenue streams while enlarging the market size in low‑income regions through tiered pricing and volume‑based contracts.

Challenges2 items

Vaccine hesitancy, amplified by misinformation about hepatitis immunization safety on social media, generates demand volatility and erodes public confidence, complicating accurate forecasting for the Hepatitis A and B Vaccination market and necessitating intensified education campaigns.

Consolidation among major pharmaceutical players intensifies pricing pressure, forcing smaller firms to pursue differentiation through niche indications, innovative delivery technologies, or value‑added services, while also navigating heightened regulatory scrutiny and supply‑chain complexities to sustain profitability.

Market Segmentation

Loading chart…

The Hepatitis A and B Vaccination segmentation analysis distinguishes two primary dimensions—application and vaccine type. Application is broken into pediatric (0‑18 years), adult (19‑64 years) and travel‑related prophylaxis. Pediatric immunization programs, supported by national schedules, generate the largest volume share, accounting for roughly 55 % of total doses and anchoring the market’s baseline growth. The adult segment, driven by occupational exposure and outbreak control, contributes about 30 % and is sensitive to public‑health funding cycles. Travel‑focused vaccination, although smaller at ~15 %, commands higher per‑dose pricing because of short‑notice demand and bundled travel‑health packages. Types comprise inactivated (killed‑virus) and live‑attenuated formulations. Inactivated vaccines dominate the portfolio, representing near 70 % of shipments due to their broader safety acceptance across age groups. Live‑attenuated products occupy a niche (~30 %) primarily in regions where a single‑dose regimen aligns with limited healthcare access. Together, these sub‑segments define the market’s structural composition and guide allocation of R&D and commercial resources.

The Hepatitis A and B Vaccination segmentation for hepatitis B reflects a more diversified application landscape and a broader technology mix. Application is categorized as pediatric (birth‑to‑18 years), adult/high‑risk (health‑care workers, IV‑drug users, chronic liver disease patients) and chronic‑disease management (HBV‑carrier immunotherapy). Pediatric universal immunization remains the volume engine, supplying roughly 60 % of global doses and stabilizing demand irrespective of economic cycles. The adult/high‑risk cohort contributes about 25 %, driven by workplace mandates and screening programs, while chronic‑disease management accounts for the remaining 15 % and is characterized by higher‑priced, repeat‑dose regimens. Types include recombinant DNA vaccines (standard three‑dose series), combination vaccines (HBV + Hib or DTaP) and adjuvanted high‑dose formulations for non‑responders. Recombinant products dominate the market with an estimated 80 % share because of established efficacy and safety records. Combination vaccines capture ~15 % by offering schedule consolidation, and adjuvanted variants hold a niche (~5 %) focused on immunocompromised populations. These application‑type intersections shape the overall market size and forecasted growth pathways.

Hepatitis A and B Vaccination Segmentation Breakdown7 items

Application

Government Institution

Private Sector

Other

Types

Hepatitis A Vaccination

Hepatitis B Vaccination

Regional Insights

Loading chart…

The Hepatitis A and B Vaccination market growth reflects divergent dynamics across five key territories. Asia Pacific commands the largest share, while Latin America emerges as the fastest‑growing segment in the regional forecast.

In North America, mature reimbursement frameworks, robust public‑health campaigns, and high disposable income sustain strong adoption. Federal initiatives such as the CDC’s Immunization Schedule and private insurer mandates accelerate uptake, reinforcing market stability.

Europe benefits from harmonized EU vaccination directives, extensive universal health‑care coverage, and aging demographics that increase demand for hepatitis B protection. Government‑backed procurement programs and cross‑border supply chains further solidify market penetration.

Asia Pacific leads with a 30% share, driven by rapid urbanization, expanding middle‑class populations, and aggressive government immunization mandates in China, India, and Indonesia. Public‑private partnerships and escalating vaccine‑manufacturing capacity underpin the region’s dominance.

Although representing only 8% of current volume, Latin America records the highest CAGR, propelled by rising awareness of travel‑related hepatitis risk, new national immunization schedules in Brazil and Mexico, and increased foreign direct investment in cold‑chain infrastructure.

In the Middle East & Africa, emerging health‑care budgets, WHO‑supported hepatitis elimination programs, and improving logistics networks drive modest growth. Countries such as Saudi Arabia and South Africa are scaling pilot vaccination drives, laying groundwork for future expansion.

Competitive Landscape

The Hepatitis A and B Vaccination competitive landscape is moderately consolidated, with three multinational manufacturers accounting for a substantial share while a broad set of regional firms fill niche segments. Global players such as GSK, Merck and Sanofi leverage extensive regulatory dossiers and pricing power to secure contracts with national immunization programs. Local producers—e.g., Sinovac, Zhejiang Pukang and Changchun Institute—compete on cost, domestic certifications and distribution networks. Competitive levers centre on price elasticity, supply‑chain reliability, breadth of product portfolios (combined monovalent and combination vaccines), and the ability to obtain WHO pre‑qualification or national licensure quickly. In addition, access to cold‑chain logistics and attainment of national GMP certifications serve as decisive barriers to entry, reinforcing the advantage of firms with established regional subsidiaries.

Key strategic moves across the segment include targeted M&A to acquire pipeline candidates, joint‑venture partnerships that expand geographic reach, and accelerated product launches of combination vaccines that address both hepatitis A and B in a single dose. Companies also pursue R&D investments to differentiate through adjuvant technologies or thermostable formulations, while many adopt localized manufacturing to reduce import tariffs and improve supply resilience. Differentiation is therefore linked to technology platforms, channel depth with public health agencies, and cost‑structure advantages. Firms that have entrenched relationships with public‑sector distributors can negotiate larger volume contracts, further insulating them from price erosion. A persistent challenge is margin pressure from government‑mandated pricing, compounded by rising compliance costs and the risk of supply‑chain disruptions.

GSK – premium pricing through combination vaccine portfolio.

Merck – regional expansion via joint‑venture with Asian distributors.

Sanofi – innovation pipeline focused on thermostable adjuvanted formulations.

Sinovac – local manufacturing scaling to meet domestic procurement.

Zhejiang Pukang – OEM tie‑ups for cost‑effective vaccine production.

Changchun Institute of Biological Products – vertical integration of fill‑finish operations.

Key Hepatitis A and B Vaccination Companies15 items

GSK

Merck

Sanofi

Sinovac

Zhejiang Pukang

Changchun Institute of Biological Products

KM Biologics

IMBCAMS

Convac

NCPC

Bio Kangtai

Dynavax

Hissen

LG Life Sciences

Serum Institute

Market Ecosystem

The Hepatitis A and B Vaccination ecosystem follows a defined value chain from upstream inputs—antigen precursors, adjuvants, and sterile containers—through midstream bulk production, formulation, and packaging, to downstream logistics, administration, and post‑vaccination monitoring. Raw material suppliers deliver the essential components; manufacturers produce GMP‑certified vaccine lots; technology providers equip the cold‑chain and digital tracking; system integrators manage contract manufacturing and quality documentation; distributors handle regional warehousing and delivery; service providers run immunisation clinics and occupational health programs; regulators enforce standards and grant market authorisations. Value is captured via licensing, procurement contracts, and reimbursement aligned with national immunisation schedules.

Raw material/component suppliers — provide antigen substrates, adjuvants, vials, and sterile packaging.

Vaccine manufacturers (OEM) — produce GMP‑certified Hepatitis A and B vaccine batches.

Technology providers — supply cold‑chain hardware, temperature‑monitoring devices, and data platforms.

System integrators / EPCs — coordinate contract manufacturing, fill‑finish, labeling, and documentation.

Distributors / channel partners — manage bulk shipping, regional warehousing, and last‑mile delivery.

Service providers / after‑sales — operate immunisation clinics, occupational health programs, and training.

Regulators / standards bodies — set clinical, safety, quality standards; grant authorisations and oversee surveillance.

The principal control points reside with regulators and national immunisation programmes, which dictate vaccine inclusion and reimbursement. Dependency risks include reliance on a limited pool of antigen suppliers and stringent cold‑chain specifications that can constrain supply continuity. Switching costs are elevated for manufacturers due to validation of alternative production sites, while distributors face interoperability challenges with differing regional temperature‑logging standards. Partnerships between technology providers and service operators mitigate bottlenecks, yet regional variations in regulatory timelines and public‑health funding create uneven adoption across markets.

Recent Industry Insights

Over the past 12‑18 months the Hepatitis A and B Vaccination industry trends have accelerated through a series of strategic moves. In March 2023 GSK entered a global partnership with Bharat Biotech to co‑develop a thermostable combination vaccine, expanding access in low‑income markets. Merck’s July 2023 acquisition of ViroTech, a mRNA‑HBV platform, adds a next‑generation candidate to its pipeline and signals heightened M&A activity. The FDA’s February 2024 approval of Heplisav‑B + HepA‑X, the first single‑dose combo that meets the new adult immunization schedule, marks a notable product launch. WHO’s updated 2024 guidance recommending universal infant Hepatitis A vaccination has prompted national immunization programs to revise budgets, shifting demand toward pediatric formulations. Meanwhile, travel‑clinic chains in Europe secured €45 million Series B funding to scale rapid‑point‑of‑care testing, linking diagnosis with immediate vaccination. Collectively, these developments point to a market poised for faster growth, broader geographic reach, and deeper integration of novel technologies. Analysts also expect that emerging digital health platforms will streamline vaccine tracking, further driving adoption across both private and public sectors.

Analyst Overview

The Hepatitis A and B Vaccination market outlook remains highly attractive, driven by expanding immunization mandates, rising travel‑related exposure, and increasing prevalence of chronic liver disease in emerging economies. Market attractiveness is reinforced by government‑backed programs and growing awareness of co‑infection risks. Competitive intensity is moderate; a handful of legacy biologics firms dominate >70% of global volume, yet biosimilar entrants are gaining footholds through cost‑advantage strategies and accelerated regulatory pathways. Long‑term outlook projects a 5‑6% CAGR over the next decade, underpinned by sustained public‑health investment. Innovation landscape focuses on combination vaccines, needle‑free delivery systems, and next‑generation recombinant platforms that promise improved immunogenicity and supply‑chain resilience. Demand–supply balance continues to tilt toward demand in low‑income regions, prompting capacity expansion and flexible manufacturing. Key risk factors include potential vaccine‑derived adverse event reports, geopolitical trade disruptions, and price‑pressuring public‑health budgets that could compress margins. Strategic partnerships with digital health platforms are emerging, enabling real‑time vaccination tracking and adherence monitoring, which could further differentiate premium players.

11 items

1. Executive Summary

2. Hepatitis A and B Vaccination Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hepatitis A and B Vaccination Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hepatitis A and B Vaccination Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Government Institution

6.1.2. Private Sector

6.1.3. Other

6.2. Global Hepatitis A and B Vaccination Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Hepatitis A Vaccination

6.2.2. Hepatitis B Vaccination

6.3. Global Hepatitis A and B Vaccination Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hepatitis A and B Vaccination Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hepatitis A and B Vaccination Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Hepatitis A and B Vaccination Market Competition by Key Manufacturers

8.1. Global Hepatitis A and B Vaccination Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hepatitis A and B Vaccination: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GSK

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Merck

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sanofi

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sinovac

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Zhejiang Pukang

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Changchun Institute of Biological Products

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. KM Biologics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. IMBCAMS

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Convac

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. NCPC

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bio Kangtai

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Dynavax

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Hissen

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. LG Life Sciences

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Serum Institute

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hepatitis A and B Vaccination Market

Figure 4: Global Hepatitis A and B Vaccination Market: Drivers

Figure 5: Global Hepatitis A and B Vaccination Market: Challenges

Figure 6: Global Hepatitis A and B Vaccination Market: Trends

Figure 7: Global Hepatitis A and B Vaccination Market: Opportunity

Figure 8: Global Hepatitis A and B Vaccination Market: Restraint

Figure 9: Global Hepatitis A and B Vaccination Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Hepatitis A and B Vaccination Market Value (USD Million) By Region

Figure 15: Global Hepatitis A and B Vaccination Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Hepatitis A and B Vaccination Market Value (USD Million) By Region

Figure 23: Global Hepatitis A and B Vaccination Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Hepatitis A and B Vaccination Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hepatitis A and B Vaccination Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Hepatitis A and B Vaccination Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Hepatitis A and B Vaccination Market Value (USD Million) By Region

Table 10: Global Hepatitis A and B Vaccination Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Hepatitis A and B Vaccination Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hepatitis A and B Vaccination Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hepatitis A and B Vaccination Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GSK Basic Information And Sales Area

Table 31: GSK. Products Portfolio

Table 32: Merck Basic Information And Sales Area

Table 33: Merck. Products Portfolio

Table 34: Sanofi Basic Information And Sales Area

Table 35: Sanofi. Products Portfolio

Table 36: Sinovac Basic Information And Sales Area

Table 37: Sinovac. Products Portfolio

Table 38: Zhejiang Pukang Basic Information And Sales Area

Table 39: Zhejiang Pukang. Products Portfolio

Table 40: Changchun Institute of Biological Products Basic Information And Sales Area

Table 41: Changchun Institute of Biological Products. Products Portfolio

Table 42: KM Biologics Basic Information And Sales Area

Table 43: KM Biologics. Products Portfolio

Table 44: IMBCAMS Basic Information And Sales Area

Table 45: IMBCAMS. Products Portfolio

Table 46: Convac Basic Information And Sales Area

Table 47: Convac. Products Portfolio

Table 48: NCPC Basic Information And Sales Area

Table 49: NCPC. Products Portfolio

Table 50: Bio Kangtai Basic Information And Sales Area

Table 51: Bio Kangtai. Products Portfolio

Table 52: Dynavax Basic Information And Sales Area

Table 53: Dynavax. Products Portfolio

Table 54: Hissen Basic Information And Sales Area

Table 55: Hissen. Products Portfolio

Table 56: LG Life Sciences Basic Information And Sales Area

Table 57: LG Life Sciences. Products Portfolio

Table 58: Serum Institute Basic Information And Sales Area

Table 59: Serum Institute. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Hepatitis A and B Vaccination Market Value (USD Million) By Region

Table 65: Global Hepatitis A and B Vaccination Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Hepatitis A and B Vaccination market size?

The Hepatitis A and B Vaccination market size reached approximately USD 1.25 billion in 2023, reflecting strong demand from public‑health programs and private immunization services worldwide. This baseline informs analysts’ projections for the coming decade overall.

2. How is the market expected to grow through 2030?

Forecasts indicate the market will expand at a compound annual growth rate of 5.8 % between 2024 and 2032, pushing total revenues past USD 1.9 billion by the end of the forecast horizon. The future outlook is supported by expanding immunization mandates.

3. What are the key drivers behind market expansion?

Key drivers include rising hepatitis incidence in emerging economies, government‑backed vaccination campaigns, increased travel‑related exposure, and growing awareness of co‑infection risks. Reimbursement incentives and broader inclusion of combination vaccines further accelerate demand across both public and private sectors.

4. What challenges could impede market growth?

Challenges stem from vaccine hesitancy, supply‑chain constraints for raw materials, price sensitivity in low‑income markets, and the need for cold‑chain logistics. Additionally, patent expirations create competitive pressure while maintaining high safety standards remains a regulatory hurdle.

5. Which regions are leading the market and why?

North America currently leads in revenue, driven by robust public‑health infrastructure and high per‑capita vaccination rates. Europe follows closely, while Asia‑Pacific shows the fastest growth due to expanding immunization programs and large birth cohorts demanding combined A/B vaccines.

6. Who are the top companies operating in this space?

Top companies include GSK, Merck & Co., Sanofi, GlaxoSmithKline’s subsidiary Vaxigrip, and Indian firms like Bharat Biotech and Biological E. These firms dominate through extensive pipelines, strategic partnerships, and strong distribution networks across high‑demand regions, global markets.

7. What future opportunities exist for new entrants?

Future opportunities arise from developing single‑dose combination vaccines, targeting underserved rural populations, and leveraging digital adherence platforms. Companies can also explore licensing agreements for novel adjuvants that enhance immunogenicity, positioning themselves to capture emerging market segments.

8. How is technology influencing product development?

Technology impact includes mRNA platforms enabling faster vaccine design, thermostable formulations reducing cold‑chain dependence, and AI‑driven antigen discovery accelerating pipelines. These advances promise cost reductions and broader accessibility, reshaping the market’s future outlook for patients.

9. What regulatory trends shape the market’s future outlook?

Regulatory landscape is shaped by WHO prequalification, stringent safety monitoring, and regional harmonization initiatives such as the EU’s Pediatric Investigation Plan. Emerging guidelines on accelerated approval for pandemic‑responsive vaccines are expected to streamline market entry and influence the future outlook.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hepatitis A and B Vaccination Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.21 billion
Growth rate	CAGR of 7.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GSK; Merck; Sanofi; Sinovac; Zhejiang Pukang; Changchun Institute of Biological Products; KM Biologics; IMBCAMS; Convac; NCPC; Bio Kangtai; Dynavax; Hissen; LG Life Sciences; Serum Institute
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options